$BEAM

Beam Therapeutics Inc.

CIK:0001745999|SEC Filings

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
License and collaboration revenue	$ 490	$ 8,466	$ 32,228	$ 15,936
Revenue, Product and Service [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 95,096	$ 101,758	$ 199,620	$ 200,574
General and administrative	31,947	26,859	66,376	54,799
Total operating expenses	127,043	128,617	265,996	255,373
Loss from operations	(126,553)	(120,151)	(233,768)	(239,437)
Other income (expense):
Change in fair value of derivative liabilities	(4,200)	1,300	(1,700)	4,500
Change in fair value of non-controlling equity investments	338	4,415	354	2,334
Change in fair value of contingent consideration liabilities	(205)	(28)	309	(55)
Gain on sale of equity method investment	455		455	0
Interest and other income (expense), net	7,487	12,326	17,354	22,190
Total other income (expense)	3,875	18,013	16,772	28,969
Net loss	(122,678)	(102,138)	(216,996)	(210,468)
Unrealized gain (loss) on marketable securities	(1,119)	(150)	(3,300)	(669)
Comprehensive loss	$ (123,797)	$ (102,288)	$ (220,296)	$ (211,137)
Net loss per common share, basic	$ (1.18)	$ (1)	$ (2.09)	$ (2.21)
Net loss per common share, diluted	$ (1.18)	$ (1)	$ (2.09)	$ (2.21)
Weighted - average common shares outstanding, basic	104,326,669	101,995,184	103,797,276	95,023,977
Weighted - average common shares outstanding, diluted	104,326,669	101,995,184	103,797,276	95,023,977

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities
Net loss	$ (216,996)	$ (210,468)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	11,015	11,066
Amortization of investment discount (premiums)	(5,368)	(8,467)
Amortization of debt discount	99	0
Stock-based compensation expense	38,322	51,049
Change in operating lease right-of-use assets	5,093	5,297
Change in fair value of derivative liabilities	1,700	(4,500)
Change in fair value of contingent consideration liabilities	(309)	55
Change in fair value of non-controlling equity investments	(354)	(2,334)
Loss (gain) on disposal of property and equipment	44
Gain on sale of equity method investment	(455)	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,328)	2,827
Accounts payable	3,430	6,435
Accrued expenses and other liabilities	(14,943)	(8,590)
Operating lease liabilities	(7,023)	(6,622)
Deferred revenue	(6,659)	(15,936)
Other long-term liabilities	123	(146)
Net cash provided by (used in) operating activities	(194,609)	(180,334)
Investing activities
Purchases of property and equipment	(4,646)	(6,201)
Purchases of marketable securities	(334,708)	(673,111)
Maturities of marketable securities	354,293	383,812
Proceeds from sale of equity method investment	455	0
Net cash provided by (used in) investing activities	15,394	(295,500)
Financing activities
Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs	0	470,513
Proceeds from issuances of stock under ESPP	1,510	1,501
Proceeds from exercise of stock options	9,548	2,474
Proceeds from the issuance of debt, net of fees paid to lender	93,886	0
Payments of debt issuance costs	(813)	0
Net cash provided by (used in) financing activities	104,131	474,488
Net change in cash, cash equivalents and restricted cash	(75,084)	(1,346)
Cash, cash equivalents and restricted cash—beginning of period	301,620	290,111
Cash, cash equivalents and restricted cash—end of period	226,536	288,765
Supplemental disclosure of cash flow information:
Cash paid for interest	2,569	0
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment additions in accounts payable and accrued expenses	$ 814	$ 972

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 219,825	$ 294,944
Marketable securities	933,102	950,266
Prepaid expenses and other current assets	25,668	23,478
Total current assets	1,178,595	1,268,688
Property and equipment, net	97,606	104,500
Restricted cash	6,711	6,676
Operating lease right-of-use assets	95,586	100,679
Other assets	7,857	634
Total assets	1,386,355	1,481,177
Current liabilities:
Accounts payable	13,099	10,231
Accrued expenses and other current liabilities	40,406	55,267
Current portion of derivative liabilities	9,400	7,700
Current portion of deferred revenue	0	6,659
Current portion of lease liability	15,207	14,364
Current portion of contingent consideration liabilities	2,771	2,714
Total current liabilities	80,883	96,935
Long-term lease liability	131,893	139,759
Long-term portion of contingent consideration liabilities	5,586	5,952
Long-term portion of debt	100,258
Other liabilities	293	173
Total liabilities	318,913	242,819
Commitments and contingencies (See Note 7, License and other agreements and Note 8, Collaboration agreements)
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at June 30, 2026 and December 31, 2025, respective
Common stock, $0.01 par value; 250,000,000 shares authorized, 103,264,636 and 101,748,962 issued and outstanding at June 30, 2026 and December 31, 2025, respectively	1,033	1,017
Additional paid-in capital	2,926,813	2,877,449
Accumulated other comprehensive (loss) income	(2,189)	1,111
Accumulated deficit	(1,858,215)	(1,641,219)
Total stockholders' equity	1,067,442	1,238,358
Total liabilities and stockholders' equity	$ 1,386,355	$ 1,481,177